home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
Post navigation
Previous Post
Previous
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
Next Post
Next
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma